-+ 0.00%
-+ 0.00%
-+ 0.00%

FIRST TRACKS BIOTHERAPEUTICS TO ANNOUNCE TOP-LINE DATA FROM COHORT 1 OF PHASE 1B TRIAL OF ANB033, A CD122 ANTAGONIST, IN CELIAC DISEASE ON OCT. 12, 2026

Reuters·10/11/2026 20:02:01